Cansativa is awarded the contract to sell cannabis flowers from German cultivation
The cannabis agency of the Federal Institute for Drugs and Medical Devices (BfArM) commissions Cansativa to provide logistics and services for the wholesale trade with all German cannabis cultivation. The contract for the distribution of cannabis for medical purposes with a total volume of 10.4 tons was awarded for four year.
Cansativa GmbH (“Cansativa”) announced yesterday that it was the only company to be awarded the contract for logistics and services in the wholesale of cannabis flowers from German cultivation from the Federal Institute for Drugs and Medical Devices (BfArM).
On behalf of the cannabis agency, Cansativa will sell the cannabis flowers from German cultivation to pharmacies and be responsible for storage, order picking and outbound logistics, among other things.
“We are proud that our offer and our expertise in the field of medicinal cannabis were able to convince the BfArM and that we were awarded the contract. It is an important step for all patients in Germany, who will have access to new products. We are honored to be able to make a contribution to sustainable security of supply with our services on behalf of the cannabis agency, ”says Jakob Sons, co-founder and co-managing director of Cansativa.
As a result of the award, Cansativa will in future be responsible for centrally distributing the cannabis flowers grown by Aurora, Aphria and Demecan in Germany on behalf of the cannabis agency. The contract term with the BfArM extends over four years with a total volume of up to 10.4 tons.
Cansativa has been importing and distributing medicinal cannabis to a large number of German pharmacies for over two years. The German market is the largest and fastest growing market for medical cannabis in Europe. With a comprehensive range of products from leading international manufacturers such as Aurora, Bedrocan, Tweed and Tilray, Cansativa has developed as an independent “one-stop shop” into a specialized wholesaler and central point of contact for medical cannabis in the German market.
“We are pleased that we can now use our experience from our previous business activities for the BfArM. With our extensive product portfolio, we act nationally and internationally as an independent wholesale partner and set ourselves the goal of further professionalising the market. We aim to further strengthen Cansativa as a central platform for the purchase and sale of medicinal cannabis, ”says Benedikt Sons, co-founder and co-managing director of Cansativa.
Cansativa is considered a pioneer in the industry and is continuously working to improve the supply situation for medical cannabis.
In this German article at FAZ Falk Heunemann covers the entire story:
